Compare · LEXX vs NVO
LEXX vs NVO
Side-by-side comparison of Lexaria Bioscience Corp. (LEXX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEXX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $208.51B, about 1770.9x LEXX ($117.7M).
- Over the past year, LEXX is down 60.8% and NVO is up 0.3% - NVO leads by 61.0 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for LEXX).
- NVO has more recent analyst coverage (25 ratings vs 0 for LEXX).
- Company
- Lexaria Bioscience Corp.
- Novo Nordisk A/S
- Price
- $5.00+4.17%
- $48.32+2.61%
- Market cap
- $117.7M
- $208.51B
- 1M return
- -41.00%
- -0.63%
- 1Y return
- -60.78%
- +0.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 5
- Recent ratings
- 0
- 25
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LEXX
- Lexaria Bioscience Corp. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Lexaria Announces Effective Date for Reverse Stock Split
- SEC Form 10-Q filed by Lexaria Bioscience Corp.
- Lexaria Updates Business Development
- Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
- Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
- GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
- Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
- Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
- Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S